Cosby A Stone1, Yiwei Liu2, Mary V Relling2, Matthew S Krantz3, Amanda L Pratt4, Andrew Abreo4, Jonathan A Hemler5, Elizabeth J Phillips6. 1. Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn. Electronic address: cosby.a.stone@vanderbilt.edu. 2. Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tenn. 3. Departments of Medicine and Pediatrics, Vanderbilt University Medical Center, Nashville, Tenn. 4. Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn. 5. Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tenn. 6. Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
Abstract
BACKGROUND: The most common immediate hypersensitivity to macrogols is associated with polyethylene glycol (PEG) 3350; however, the epidemiology, mechanisms, and cross-reactivity are poorly understood. Thousands of medications contain either PEGs or structurally similar polysorbates. OBJECTIVE: Our objective was to better understand the mechanism, cross-reactivity, and scope of PEG hypersensitivity. METHODS: Two cases with a past history of immediate hypersensitivity to PEG-containing medications were used to study potential mechanisms and cross-reactivity of immediate reactions to PEG 3350. Skin testing and oral challenges with PEG and polysorbate-containing agents were employed to determine clinical reactivity and cross-reactivity between the 2 allergens. Enzyme-linked immunosorbent assay and electrochemiluminescent immunoassay were used to detect anti-PEG specific IgG and IgE, respectively, using PEGylated protein or PEG alone as antigens in 2 cases and 6 PEG 3350 tolerant controls. We searched US Food and Drug Administration (FDA) adverse event reports for immediate reactions to PEG 3350 to determine the potential scope of this problem in the United States. RESULTS: Skin and provocation testing demonstrated symptomatic reactivity in both cases to PEG 3350 and polysorbate 80. Plasma samples were positive for anti-PEG specific IgE and IgG antibodies only in cases and binding increased directly proportional to the molecular weight of PEG tested. FDA adverse event reports revealed 53 additional cases of possible PEG 3350 anaphylaxis. CONCLUSIONS: Immediate hypersensitivity to PEG 3350 with cross-reactive polysorbate 80 hypersensitivity may be underrecognized in clinical practice and can be detected with clinical skin testing. Our studies raise the possibility of an IgE-mediated type I hypersensitivity mechanism in some cases.
BACKGROUND: The most common immediate hypersensitivity to macrogols is associated with polyethylene glycol (PEG) 3350; however, the epidemiology, mechanisms, and cross-reactivity are poorly understood. Thousands of medications contain either PEGs or structurally similar polysorbates. OBJECTIVE: Our objective was to better understand the mechanism, cross-reactivity, and scope of PEGhypersensitivity. METHODS: Two cases with a past history of immediate hypersensitivity to PEG-containing medications were used to study potential mechanisms and cross-reactivity of immediate reactions to PEG 3350. Skin testing and oral challenges with PEG and polysorbate-containing agents were employed to determine clinical reactivity and cross-reactivity between the 2 allergens. Enzyme-linked immunosorbent assay and electrochemiluminescent immunoassay were used to detect anti-PEG specific IgG and IgE, respectively, using PEGylated protein or PEG alone as antigens in 2 cases and 6 PEG 3350 tolerant controls. We searched US Food and Drug Administration (FDA) adverse event reports for immediate reactions to PEG 3350 to determine the potential scope of this problem in the United States. RESULTS: Skin and provocation testing demonstrated symptomatic reactivity in both cases to PEG 3350 and polysorbate 80. Plasma samples were positive for anti-PEG specific IgE and IgG antibodies only in cases and binding increased directly proportional to the molecular weight of PEG tested. FDA adverse event reports revealed 53 additional cases of possible PEG 3350 anaphylaxis. CONCLUSIONS: Immediate hypersensitivity to PEG 3350 with cross-reactive polysorbate 80hypersensitivity may be underrecognized in clinical practice and can be detected with clinical skin testing. Our studies raise the possibility of an IgE-mediated type I hypersensitivity mechanism in some cases.
Authors: C A Fernandez; E Stewart; J C Panetta; M R Wilkinson; A R Morrison; F D Finkelman; J T Sandlund; C H Pui; S Jeha; M V Relling; P K Campbell Journal: Cancer Chemother Pharmacol Date: 2014-04-27 Impact factor: 3.333
Authors: Jonathan K Armstrong; Georg Hempel; Susanne Koling; Linda S Chan; Timothy Fisher; Herbert J Meiselman; George Garratty Journal: Cancer Date: 2007-07-01 Impact factor: 6.860
Authors: Cosby A Stone; Christine R F Rukasin; Thomas M Beachkofsky; Elizabeth J Phillips Journal: Br J Clin Pharmacol Date: 2019-11-05 Impact factor: 4.335
Authors: Da Shi; Damian Beasock; Adam Fessler; Janos Szebeni; Julia Y Ljubimova; Kirill A Afonin; Marina A Dobrovolskaia Journal: Adv Drug Deliv Rev Date: 2021-12-10 Impact factor: 15.470
Authors: Zhao-Hua Zhou; Cosby A Stone; Baruch Jakubovic; Elizabeth J Phillips; Gordon Sussman; JuMe Park; Uyen Hoang; Susan L Kirshner; Robert Levin; Steven Kozlowski Journal: J Allergy Clin Immunol Pract Date: 2020-11-17
Authors: Sabine Altrichter; Stefan Wöhrl; Fritz Horak; Marco Idzko; Galateja Jordakieva; Eva Untersmayr; Zsolt Szepfalusi; Petra Zieglmayer; Erika Jensen-Jarolim; Ursula Wiedermann; Alexander Rosenkranz; Wolfram Hötzenecker Journal: Allergo J Int Date: 2021-07-14